Imiquimod 5% Cream as Adjunctive Therapy For Primary, Solitary, Nodular Nasal Basal Cell Carcinomas Before Mohs Micrographic Surgery: A Randomized, Double Blind, Vehicle‐Controlled Study

@article{Butler2009Imiquimod5C,
  title={Imiquimod 5\% Cream as Adjunctive Therapy For Primary, Solitary, Nodular Nasal Basal Cell Carcinomas Before Mohs Micrographic Surgery: A Randomized, Double Blind, Vehicle‐Controlled Study},
  author={David F. Butler and Palak K Parekh and Armando Lenis},
  journal={Dermatologic Surgery},
  year={2009},
  volume={35},
  pages={24–29}
}
BACKGROUND Imiquimod 5% cream is currently approved for treatment of nonfacial, superficial basal cell carcinomas (BCCs). Topical imiquimod might be a reasonable candidate for adjunctive therapy of nodular, nasal BCCs before Mohs surgery. OBJECTIVE To observe the effectiveness of imiquimod 5% cream in reducing the number of Mohs stages, defect size, cost of Mohs surgery, and reconstruction. METHODS Patients applied the study medication nightly for 6 weeks with occlusion followed by a 4-week… 
Imiquimod 5% Cream: A Review of Its Safety and Efficacy in the Management of Superficial Basal Cell Carcinoma
TLDR
The safety and efficacy of imiquimod 5% cream is reviewed, its effectiveness in the treatment of nodular and facial basal cell carcinomas is reported on, and its role as an adjunctive therapy is commented on.
Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma
TLDR
Evaluation of long-term safety and efficacy of topical imiquimod treatment in various BCC subtypes and locations, with individualized treatment duration found treatment success was high among the study patients with various histological subtypes, with good long- term cosmetic results.
Immunocryosurgery for non-superficial basal cell carcinoma: a pro-spective, open-label phase III study for tumours ≤ 2 cm in diameter.
TLDR
The results show a high therapeutic efficacy of immunocryosurgery in a large series of primary non-superficial BCC in patients with 134 basal cell carcinoma.
Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study
TLDR
Imiquimod 5% cream could be used as a pretreatment of Mohs micrographic surgery (MMS) to decrease defect size.
Inaugural International Traveling Chair of Dermatologic Surgery International Society of Dermatologic Surgery Imiquimod 5% Cream as Adjunctive Therapy for Primary, Solitary, Nodular Basal Cell Carcinomas Before Mohs Micrographic Surgery: A Randomized, Double-Blind, Vehicle-Controlled Study
  • 2010
the biologic dressing ‘‘Op-site’’ (Smith & Nephew Limited, Welwyn Garden City, England) when covering flap reconstructions. This was reiterated in the Schoch Letter and published in the Journal of
Efficacy and safety of imiquimod 5% cream for basal cell carcinoma: a meta-analysis of randomized controlled trial
TLDR
The present meta-analysis indicated the effects of imiquimod in improving the histological/composite clearance rates as compared with other treatments.
A Review on Imiquimod Therapy and Discussion on Optimal Management of Basal Cell Carcinomas
TLDR
Examination of the existing information available on the use of imiquimod for BCC and comparing it to other treatment modalities suggests that response to treatment may depend on location of lesion, thus more research must be done in this area.
Skin reaction to imiquimod self-treatment in post-menopausal women. A case report
TLDR
It is noted that using imiquimod in postmenopausal women without medical advice, especially in post menopausal women, could represent a higher risk of skin lesions which need specialized medical treatment.
Topical imiquimod as neoadjuvant therapy before Mohs micrographic surgery for basal cell carcinoma in the head and neck region: findings from a large retrospective study
TLDR
Basal cell carcinoma is the most common cutaneous malignancy, with incidence rates increasing worldwide during the last few decades, and the majority of the lesions are located on the face.
Commentary: Inflammation and Fibrosis: Pitfalls for the Mohs Surgeon
  • J. Geisse
  • Medicine
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • 2013
TLDR
Treating superficial basal cell carcinoma (BCC), which is characterized by areas of regression resulting in papillary dermal fibrosis, is particularly challenging when encountered in association with multiple cryosurgical scars.
...
1
2
3
4
...

References

SHOWING 1-10 OF 26 REFERENCES
Imiquimod Treatment of Superficial and Nodular Basal Cell Carcinoma: 12‐Week Open‐Label Trial
TLDR
Treatment of superficial BCCs with topical imiquimod for 12 weeks produced an excellent clinical response overall, with complete remission maintained after a mean of 23 months of follow-up.
Topical Imiquimod Treatment for Nodular Basal Cell Carcinomas: An Open‐Label Series
TLDR
Imiquimod 5% cream may be another treatment modality for nodular BCC after 12 weeks for three times a week application and at the 18-month follow-up, no patients had recurrent tumor.
Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens.
TLDR
Dosing once daily for 7 days per week resulted in the highest clearance rate, with 25 of 35 and 16 of 21 patients showing clearance of their tumor in the 6- and 12-week studies, respectively.
5% Imiquimod Cream and Reflectance‐Mode Confocal Microscopy as Adjunct Modalities to Mohs Micrographic Surgery for Treatment of Basal Cell Carcinoma
TLDR
Imiquimod improved excision results relative to vehicle when used for treating basal cell carcinoma before Mohs micrographic surgery, suggesting that confocal microscopy may help determine the need for surgery.
Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma.
TLDR
Imiquimod, a topical immune response modifier, belongs to the family of immunostimulators, and has successfully treated both superficial and nodular basal cell carcinomas through the localized activation of elaborate immune response.
Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo.
TLDR
Tumor cells became more susceptible to apoptosis through decreased Bcl-2 expression after treatment with 5% imiquimod cream, and induced a massive increase in macrophage peritumoral and intratumoral infiltration.
Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low‐frequency dosing with and without occlusion
TLDR
Imiquimod 5% cream has been investigated for non‐surgical treatment of superficial and nodular basal cell carcinoma (BCC) tumours.
...
1
2
3
...